繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

argenx强调2026年战略优先事项,第四季度销售额达到12.9亿美元,2025年初步净销售额总计41.5亿美元

2026-01-12 14:32

  • Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
  • VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026
  • Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches
  • Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。